

Infection Control & Hospital Epidemiology

<http://journals.cambridge.org/ICE>

Additional services for *Infection Control & Hospital Epidemiology*:

Email alerts: [Click here](#)

Subscriptions: [Click here](#)

Commercial reprints: [Click here](#)

Terms of use : [Click here](#)

Preadmission Application of 2% Chlorhexidine Gluconate (CHG): Enhancing Patient Compliance While Maximizing Skin Surface Concentrations

Charles E. Edmiston, Jr, Candace J. Krepel, Maureen P. Spencer, Alvaro A. Ferraz, Gary R. Seabrook, Cheong J. Lee, Brian D. Lewis, Kellie R. Brown, Peter J. Rossi, Michael J. Malinowski, Sarah E. Edmiston, Edmundo M. Ferraz and David J. Leaper

Infection Control & Hospital Epidemiology / *FirstView* Article / January 2016, pp 1 - 6

DOI: 10.1017/ice.2015.303, Published online: 28 December 2015

Link to this article: http://journals.cambridge.org/abstract_S0899823X15003037

How to cite this article:

Charles E. Edmiston, Jr, Candace J. Krepel, Maureen P. Spencer, Alvaro A. Ferraz, Gary R. Seabrook, Cheong J. Lee, Brian D. Lewis, Kellie R. Brown, Peter J. Rossi, Michael J. Malinowski, Sarah E. Edmiston, Edmundo M. Ferraz and David J. Leaper Preadmission Application of 2% Chlorhexidine Gluconate (CHG): Enhancing Patient Compliance While Maximizing Skin Surface Concentrations. *Infection Control & Hospital Epidemiology*, Available on CJO 2015 doi:10.1017/ice.2015.303

Request Permissions : [Click here](#)

Preadmission Application of 2% Chlorhexidine Gluconate (CHG): Enhancing Patient Compliance While Maximizing Skin Surface Concentrations

Charles E. Edmiston, Jr, PhD;^{1,2} Candace J. Krepel, MS;^{1,2} Maureen P. Spencer, M.Ed;³ Alvaro A. Ferraz, PhD, MD;⁴ Gary R. Seabrook, MD;¹ Cheong J. Lee, MD;¹ Brian D. Lewis, MD;¹ Kellie R. Brown, MD;¹ Peter J. Rossi, MD;¹ Michael J. Malinowski, MD;¹ Sarah E. Edmiston, M.Ed;² Edmundo M. Ferraz, PhD, MD;⁴ David J. Leaper, MD⁵

OBJECTIVE. Surgical site infections (SSIs) are responsible for significant morbidity and mortality. Preadmission skin antisepsis, while controversial, has gained acceptance as a strategy for reducing the risk of SSI. In this study, we analyze the benefit of an electronic alert system for enhancing compliance to preadmission application of 2% chlorhexidine gluconate (CHG).

DESIGN, SETTING, AND PARTICIPANTS. Following informed consent, 100 healthy volunteers in an academic, tertiary care medical center were randomized to 5 chlorhexidine gluconate (CHG) skin application groups: 1, 2, 3, 4, or 5 consecutive applications. Participants were further randomized into 2 subgroups: with or without electronic alert. Skin surface concentrations of CHG ($\mu\text{g/mL}$) were analyzed using a colorimetric assay at 5 separate anatomic sites.

INTERVENTION. Preadmission application of chlorhexidine gluconate, 2%

RESULTS. Mean composite skin surface CHG concentrations in volunteer participants receiving EA following 1, 2, 3, 4, and 5 applications were 1,040.5, 1,334.4, 1,278.2, 1,643.9, and 1,803.1 $\mu\text{g/mL}$, respectively, while composite skin surface concentrations in the no-EA group were 913.8, 1,240.0, 1,249.8, 1,194.4, and 1,364.2 $\mu\text{g/mL}$, respectively (ANOVA, $P < .001$). Composite ratios (CHG concentration/minimum inhibitory concentration required to inhibit the growth of 90% of organisms [MIC^{90}]) for 1, 2, 3, 4, or 5 applications using the 2% CHG cloth were 208.1, 266.8, 255.6, 328.8, and 360.6, respectively, representing CHG skin concentrations effective against staphylococcal surgical pathogens. The use of an electronic alert system resulted in significant increase in skin concentrations of CHG in the 4- and 5-application groups ($P < .04$ and $P < .007$, respectively).

CONCLUSION. The findings of this study suggest an evidence-based standardized process that includes use of an Internet-based electronic alert system to improve patient compliance while maximizing skin surface concentrations effective against MRSA and other staphylococcal surgical pathogens.

Infect. Control Hosp. Epidemiol. 2015;1–6

The Centers for Disease Control and Prevention (CDC) has reported that 51.4 million inpatient surgical procedures were performed in the United States in 2010.¹ Surgical site infections (SSIs) are the most common healthcare-associated infection, and it has been estimated that more than 500,000 SSIs occur in the United States each year, with an associated mortality approaching 25%.^{2–7} While these numbers have been extrapolated from inpatient procedures alone, the actual number of SSIs is likely to be much higher because more than 30 million surgical procedures are performed annually in outpatient ambulatory surgical centers (ASCs).⁸

The 1999 the CDC Surgical Site Infection Prevention guidelines designated the preadmission antiseptic shower as a category 1B (strongly recommended) clinical practice.⁹ A study published in 2011 found that many of the early clinical studies, which reported no clinical benefit associated with preoperative antiseptic showering, were technically flawed, lacking in rigorous standardization.¹⁰ Several authors have noted that most of the early studies lack a patient compliance metric, which can minimize the benefit of any patient-centered intervention. The reasons associated with patient noncompliance often include failure to understand

Affiliations: 1. Department of Surgery (Division of Vascular Surgery), Research Laboratory, Medical College of Wisconsin, Milwaukee, Wisconsin; 2. Surgical Microbiology Research Laboratory, Medical College of Wisconsin, Milwaukee, Wisconsin; 3. Infection Prevention Consultants, Boston, Massachusetts; 4. Department of Surgery, Pernambuco University, Recife, Brazil; 5. Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield, United Kingdom.

Received August 15, 2015; accepted November 9, 2015

© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved. DOI: 10.1017/ice.2015.303

administrative instructions, use of unfamiliar medical terminology, social isolation, language barriers, low educational levels, illiteracy, and socioeconomic status.¹¹

Reminder-based interventions (repeated cues) have been shown to be beneficial in enhancing patient compliance (or adherence) to taking prescription medication.¹² A recent study using short message service (SMS) texting, e-mail, or voicemail technology documented the benefits of using an electronic reminder to enhance compliance to a preadmission showering protocol using 4% aqueous chlorhexidine gluconate (CHG).¹³ The present study was designed to assess the impact of an electronic alert system (SMS texting, e-mail, or voicemail) on compliance to a standardized preadmission application of 2% CHG delivered using a polyester cloth containing 500 mg of CHG. The study was also designed to assess the impact of multiple (1, 2, 3, 4, and 5) applications of 2% CHG on skin surface concentrations at 5 separate anatomic sites. Compliance was evaluated using a colorimetric analysis to determine skin surface concentrations of CHG.

METHODS AND MATERIALS

Randomized Study Groups

The preadmission CHG skin application study protocol was reviewed and approved by the Medical College of Wisconsin Institutional Review Board. Following oral and written consent, study participants were randomized into 1 of 5 study groups. The participants were further randomized into 2 subgroups: Group A: 2% CHG, 1 application (morning) (N=20) with subgroup A1 (electronic alert group, N=10) and subgroup A2 (no electronic alert group, N=10); Group B: 2% CHG 2 applications (1 night/1 morning) (N=20) with subgroup B1 (electronic alert group, N=10) and subgroup B2 (no electronic alert group, N=10); Group C: 2% CHG 3 applications (2 nights/1 morning) (N=20) with subgroup C1 (electronic alert group, N=10) and subgroup C2 (no electronic alert group, N=10); Group D: 2% CHG 4 applications (3 night/1 morning) (N=20) with subgroup D1 (electronic alert group, N=10) and subgroup D2 (no electronic alert group, N=10); and Group E: 2% CHG 5 applications (4 nights/1 morning) (N=20) with subgroup E1 (electronic alert group, N=10) and subgroup E2 (no electronic alert group, N=10).

CHG Preadmission Cleansing Protocol

All study participants received both oral and written instructions on how to apply CHG to the body surfaces using a 2% CHG-coated polyester cloth containing 500 mg of CHG (Sage Products, Cary, IL). The participants were instructed not to use the cloths immediately after taking a hot shower but rather to wait 30–60 minutes before application. The 2% CHG cloths were provided in sealed packs with 2 cloths per package, and each participant was given 3 packages per application interval (total of 6 cloths) with instructions to use 1 cloth on each

selected area of the body (biceps to wrist, abdomen, thighs to ankles). Participants were instructed to thoroughly apply the CHG-laden cloth to each designated surface for a minimum period of 1 minute followed by a repetition of the application process for an additional 1 minute using the reverse side of the polyester cloth. If the extra cloth was not used, it was discarded. The volunteers in groups A1, B1, C1, D1, and E1 were asked their preference for receiving an electronic alert prior to each application event (SMS text message, e-mail, or voicemail). The individualized reminders were entered into an Internet-based menu (PrepCheck Early Preop Prep Patient Reminder System, Sage Products, Cary, IL). The reminder options ranged from 1 to 4 nights, including the morning of the hypothetical surgery. All study participants were required to return to the Surgical Microbiology Research Laboratory in the Department of Surgery at the Medical College of Wisconsin within 3–4 hours after the last (morning) application of 2% CHG to assess skin surface concentrations. The participants were instructed that if they experienced any significant tingling or burning sensation following application of CHG, they should liberally rinse the affected area with water and immediately contact the principal investigator (CEE) or study coordinator (CJK). All participants were told to gently apply the CHG-laden cloth to all designated surfaces, avoiding any vigorous rubbing or harsh scrubbing of the skin surface because previous observations indicated that some individuals experience redness and/or irritation following vigorous application of the CHG-laden polyester cloth. The study volunteers were also instructed not to apply any lotions, oils, or creams to the prepared areas for the duration of the study because these surface agents mask the activity of CHG, interfering with colorimetric analysis. The timing and return for CHG skin-surface determination was scheduled for 10–14 days after informed consent, randomization, and receiving supplies. The volunteers were required to return all empty packaging as a required component of study completion.

Measurement of CHG Skin Surface Concentrations

The CHG skin-surface concentration assay is based on an adaptation of a US Official Monograph for the Identification of Chlorhexidine Gluconate Solution.^{14,15} The standard method was modified to allow portability and ease of use by clinicians for point-of-use testing. In brief, a Bio-Swab (Arrowhead Forensics, Lenexa, KS) was used to sample a defined skin surface area (2 cm² template) on the right–left antecubital fossae, the right–left popliteal fossae, and the abdomen by rolling the swab back and forth across the skin for 30 seconds, insuring that all free surfaces (including the top of the swab) of the sampling swab made direct contact with the skin surface. The swabs were then immediately placed in a screw-cap container to prevent desiccation before analysis. A volume of 100 µL freshly prepared indicator solution [5 parts 1% cetyltrimethylammonium bromide (Sigma-Aldrich Co., St. Louis, MO) and 2 parts sodium hypobromite

(Fisher Scientific, Hanover Park, IL)] was added to each swab. A light pink to intense red color indicated the presence of CHG, with intensity of the color reflective of the relative concentration of CHG on the surface of the skin. The color reaction on each swab was compared to a freshly prepared CHG standard, which ranged between 2.5 and 10,000 µg/mL. The assay was read by an independent, blinded observer who compared test swabs with the CHG standard. A fresh standard solution was prepared daily prior to testing of volunteer sample swabs.

Statistical Analysis

The principle investigator was blinded to all randomization codes until the final participant was processed, at which point the codes were broken and individual groups were analyzed. Analysis of variance (ANOVA) and 2-sided *t* test were used to analyze the differences between the relative mean CHG skin-surface concentrations in groups A through E at the *P* < .05 level of significance. Statistical analysis was conducted using the MINITAB Statistical Program version 10 (Minitab, State College, PA).

RESULTS

A total of 6 study participants were noncompliant with the protocol; 4 participants (1 each from groups C2, D2, E1, and E2) failed to return for determination of skin surface CHG levels, and 2 participants (1 each from groups A1 and B1) broke protocol by deviating from the CHG application schedule. All of these 6 participants were replaced. None of the participants reported any significant tingling or irritation following single or multiple applications of 2% CHG; 2 participants (group B2 and D1) indicated a slight irritation but did not view this as a significant event requiring notification of the principle investigator or study coordinator.

Table 1 documents the mean time differential between the last skin application of 2% CHG and skin surface analysis for study participants. No significant difference was observed in the mean time differential between final application of 2% CHG and laboratory analysis of skin surface concentrations between all study groups. The majority of the volunteers (99 of 100) returned to the laboratory within 4 hours of the last application of CHG for skin surface analysis. Figure 1 demonstrates the mean skin surface concentrations of chlorhexidine gluconate (CHG) following 1 application (group A), 2 applications (group B), 3 applications (group C), 4 applications (group D) or 5 applications (group E) of 2% CHG to left, right antecubital fossae, abdomen, and left, right popliteal fossae. Following 1 application of 2% CHG, no significant difference was noted in mean skin surface concentrations of 2% CHG between individuals who received an electronic reminder (alerted) and participants who were not prompted (non-alerted) to complete the application process (*P* = .08). A similar finding was noted for individuals in

TABLE 1. Time Interval Between Last Application and Analysis of Chlorhexidine Gluconate, 2% Skin Surface Concentrations in Electronic Alert and Non-Alert Groups

Group	No. of Participants	Time, Mean (SD), min
A (1 application)		
A1 (electronic alert)	10	159.6 (124.5)
A2 (no electronic alert)	10	96.3 (37.6)
B (2 applications)		
B1 (electronic alert)	10	117.9 (53.7)
B2 (no electronic alert)	10	103.5 (44.0)
C (3 applications)		
C1 (electronic alert)	10	104.2 (63.9)
C2 (no electronic alert)	10	97.6 (54.6)
D (4 applications)		
D1 (electronic alert)	10	112.3 (52.5)
D2 (no electronic alert)	10	148.6 (96.9)
E (5 applications)		
E1 (electronic alert)	10	91.1 (39.7)
E2 (no electronic alert)	10	144.1 (70.7)

NOTE. ANOVA, *P* = .315.




FIGURE 1. Mean skin surface concentrations of chlorhexidine gluconate (CHG), µg/mL following 1, 2, 3, 4, and 5 applications of 2% using a polyester cloth containing 500 mg CHG; N = 20 per application group/10 per subgroup; EA = electronic alert (SMS texting, e-mail or voicemail); EA vs no EA (*P* < .001).

both the groups B and C (*P* = .54 and *P* = .67, respectively). However, mean skin surface CHG concentrations were significantly higher on sampled sites in groups B and C (alerted and non-alerted participants) than in the group A (*P* < .004). A significant difference in mean CHG skin surface concentrations was noted on designated sampling sites in participants receiving an electronic reminder in both groups D1 and E1 compared with non-alerted participants in groups D2 and E2 (*P* = .04 and *P* = .007, respectively).

Figure 2 is a dot plot, documenting on each line the mean skin surface concentrations of CHG at 5 separate anatomic locations (reading left to right on each line; left, right antecubital fossae, abdomen and left, right popliteal fossae) following




FIGURE 2. Dot plot. Impact of electronic alerts on mean skin surface concentrations of chlorhexidine gluconate. Each line represents unique subgroup; circles represent reading from left to right: left, right antecubital fossae, abdomen and left/right popliteal fossae.




FIGURE 3. Composite mean skin surface concentrations of chlorhexidine gluconate (CHG), µg/mL Following 1, 2, 3, 4, and 5 applications of 2% using a polyester cloth containing 500 mg CHG; N=20 per group/10 per subgroup; EA=electronic alert (SMS texting, e-mail or voicemail); EA vs no EA, ($P < .001$).

CHG application using a polyester cloth containing 500 mg of chlorhexidine gluconate. Notably, in participants applying CHG 2 or 3 times, skin surface concentrations ranged between 1,000 and 1,500 µg/mL regardless of whether an electronic alert was initiated. However, as the number of consecutive applications increased, electronic prompting resulted in a significantly higher skin surface concentration of CHG (ranging between 1,400 and 2,000 µg/mL) compared with the non-prompted comparator groups (ranging between 1,000 and 1,550 µg/mL). Figure 3 documents the mean composite (representing all 5 anatomic sampling sites) skin surface concentrations of CHG in alerted and non-alerted participants. In participants receiving an electronic reminder to apply the 2% CHG cloth to designated body surfaces, a significant increase in composite CHG skin surface concentrations was noted across all 5 study groups with the highest CHG concentrations

observed in those participants applying 2% CHG 4 or 5 times ($P < .001$), whereas no significant difference was noted in composite skin-surface concentrations between groups B2, C2, D2, and E2 ($P = .33$).

DISCUSSION

Many healthcare facilities have adopted a preadmission antiseptic skin protocol in an effort to reduce the endogenous microbial burden on the skin of patients undergoing elective surgery with the aim of reducing the risk of surgical site infection (SSI). This widespread practice is a topic of controversy among healthcare professionals. Historically, the practice was designated by the 1999 CDC guidelines as a category 1B clinical practice and is strongly recommended.⁹ However, no randomized clinical trials (RCTs) have documented the benefit of this practice as an effective strategy for reducing the risk of postoperative SSIs. To that point, a recent Cochrane Collaborative report stated, "This review provides no clear evidence of benefit for preoperative showering or bathing with chlorhexidine over other wash products, to reduce surgical site infection."¹⁶ Several publications, however, have questioned the methodological and operational limitations of previously published RCTs and their ability to assess the therapeutic and mechanistic benefits of applying 2% or 4% chlorhexidine gluconate to the surface of the skin prior to hospital admission.^{13,17–20}

The 2008 SHEA/IDSA SSI Practice Recommendation, while deferring to recommend a specific application policy, acknowledges that the optimal antiseptic benefits of CHG is dependent upon achieving adequate surface concentrations on the skin.²¹ This provocative comment represents the pivotal argument for implementation of a standardized preadmission strategy for application of CHG to whole or selective body surfaces. Several factors should be considered when evaluating this low-risk and low-cost intervention: (1) CHG surface skin concentrations accumulate with repetitive application; therefore, a single application is unlikely to result in sustainable CHG concentrations sufficient to inhibit skin flora. (2) Standardization is an important component of any antiseptic body cleansing or showering process; without standardization, the therapeutic benefit of preadmission skin antiseptics is questionable. (3) A discussion of measuring patient compliance is often excluded from most preadmission antiseptic protocols, thereby marginalizing the benefit of this patient-centered process.

Chlorhexidine gluconate is available in 2 forms for preadmission application; 4% aqueous CHG formulation for showering and a 2% CHG polyester (500 mg CHG) cloth for post-shower application. Recently, 2 publications have addressed the standardization and compliance process for 4% aqueous CHG, suggesting (as for any medicinal process) that timing, dose, and duration can have a significant impact on achieving high therapeutic skin-surface concentrations of CHG.¹⁹ Furthermore, patient compliance can be enhanced

using an electronic alert technology that provides SMS texting, e-mail, or voicemail to remind patients to shower with 4% aqueous CHG.¹³ The present investigation was designed to address the same questions using a polyester cloth that contained 500 mg of CHG (2%).

In the present study, multiple applications of the 2% CHG cloth resulted in a significant increase in skin surface concentrations of CHG (ANOVA, $P < .001$). The lowest documented concentration with a single application was 786.0 $\mu\text{g/mL}$ (abdomen), while the highest was 1998.9 $\mu\text{g/mL}$ (abdomen) following 5 consecutive applications over a 4-day period. The maximal mean composite skin surface CHG concentrations (Figure 3) in the alerted group following 1, 2, 3, 4, and 5 applications were 1,040.5, 1,334.4, 1,278.2, 1,643.9, and 1,803.1 $\mu\text{g/mL}$, respectively. A previous comparative study published by the present authors in 2010, following 2 consecutive applications using the 2% CHG polyester cloth, found a mean composite skin surface concentration of 1,745.7 $\mu\text{g/mL}$, representing a concentration in excess of 300 times the CHG minimum inhibitory concentration required to inhibit the growth of 90% [MIC^{90}] of most staphylococcal (including MRSA) surgical pathogens.²⁰ The composite value reported in the present analysis following 2 applications was 1,334.4 $\mu\text{g/mL}$. However, a comparison of MIC values for staphylococcal isolates, including MRSA recovered from post-operative surgical site infections within the previous 12 months (June 2014–June 2015) found no change in the CHG MIC^{90} (5.0 $\mu\text{g/mL}$) since the last analysis in 2010 (source: unpublished data, 2015 Surgical Microbiology Research Laboratory, Medical College of Wisconsin).²⁰ Therefore, using an MIC^{90} value of 5.0 $\mu\text{g/mL}$ as a comparative benchmark, the composite (CHG concentration / MIC^{90}) ratios reported for 1, 2, 3, 4, and 5 applications of CHG using the 2% CHG cloth in the EA group were 208.1, 266.8, 255.6, 328.8, and 360.6, respectively. These ratios are reflective of a substantial concentration of CHG on the surface of the skin that is effective against Gram-positive staphylococcal surgical pathogens, including drug-resistant strains.

In addition, use of an electronic alert system that allows for SMS texting, e-mail, or voicemail had a significant impact on improving patient compliance as measure by increased skin surface concentrations of CHG? Analysis of individual and composite sample site data documented that utilization of an electronic alert resulted in a significant increase in skin surface concentrations of CHG in the 4 and 5 CHG application groups; $P < .04$ and $P < .007$, respectively (Figure 3). The mean composite skin surface concentration in the single, 2 and 3 CHG application groups were higher in the alerted population compared to the group that did not receive an electronic reminder, but the values but did not reach statistical significance. The consensus regarding these findings suggests that utilization of an electronic alert system for the preadmission application of CHG using a polyester cloth containing 500 mg of CHG maximizes the composite skin-surface concentrations of CHG compared with a non-alerted population. The maximal

benefit of the electronic alert system was derived when the application period was extended beyond 2 days, when some individuals were likely to have forgotten or truncated the final application process.

The findings of this study suggest an evidence-based metric for using a CHG-laden (500 mg) polyester cloth to enhance skin concentrations, resulting in a mean composite skin-surface concentration exceeding 1,300 $\mu\text{g/mL}$ after just 2 applications. Achieving a maximal skin surface concentration of CHG using a 2% polyester cloth requires a thoughtful, standardized approach that includes a thorough and focused application process, the avoidance of any surface agents such as oils, creams, or lotions that mask or diminish therapeutic activity, and utilization of an electronic alert system to remind the patient to complete the preadmission skin antisepsis protocol. Our collective experience with the Surgical Care Project has clearly documented that poor compliance with guidelines and interventional protocols marginalizes the benefit of the best of evidence-based practices.^{22,23} The limitation of this study can be summed up as follows. Will the standardization of the preadmission cleansing process that includes the major elements of this study (i.e., multiple consecutive CHG applications combined with an electronic alert) in effect reduce the risk of SSI? Previous clinical trials have found limited or no benefit associated with taking an antiseptic shower prior to surgery, but these studies have documented flaws in both their operational and compliance components. The current study provides a pathway to improved patient compliance while maximizing skin surface concentrations of CHG, sufficient to reduce the microbial burden of wound-contaminating Gram-positive and Gram-negative microbial flora.

ACKNOWLEDGMENTS

Financial support. The study was supported in part by an unrestricted grant from Sage Products, Cary, Illinois. All comments and opinions in this manuscript represent the composition, review, and sole deliberation of the cited authors.

Potential conflicts of interest. C.E.E. and G.R.S. report having received an unrestricted grant from Sage Products, Inc. (Cary, IL). All other authors of the manuscript report no conflicts of interest relevant to this publication.

Address correspondence to Charles E. Edmiston, Jr., PhD, Division of Vascular Surgery, 9200 West Wisconsin Avenue, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 (edmiston@mcw.edu).

REFERENCES

1. National Hospital Discharge Survey: 2010 table, Procedures by selected patient characteristics—number by procedure category and age. Centers for Disease Control and Prevention website. http://www.cdc.gov/nchs/fastats/inpatient_surg.htm. Published 2010. Updated August 9, 2015. Accessed August 11, 2015.
2. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. *Public Health Rep* 2007;122:160–166.

3. Reed D, Kemmerly SA. Infection control and prevention: a review of hospital-acquired infections and the economic implications. *Oscher J* 2009;9:27–31.
4. Shepard J, Ward W, Milstone A, et al. Financial impact of surgical site infections on hospital: the hospital management perspective. *JAMA Surg* 2013;148:907–914.
5. De Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. *Am J Infect Control* 2009;37:387–397.
6. Herwaldt LA, Cullen JJ, Scholz D, et al. A prospective study of outcome, healthcare resource utilization, and cost associated with postoperative nosocomial infections. *Infect Control Hosp Epidemiol* 2006;27:1291–1298.
7. Meeks DW, Lally KP, Carrick MM, et al. Compliance with guidelines to prevent surgical site infections: as simple as 1-2-3? *Am J Surg* 2011;201:76–83.
8. Ambulatory Surgery in the United States, 2006. Centers for Disease Control and Prevention website. <http://www.cdc.gov/nchs/data/nhsr/nhsr011.pdf>. Published 2009. Accessed August 1, 2015.
9. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. The Hospital Infection Control Practice Advisory Committee: guidelines for the prevention of surgical site infections. *Am J Infect Control* 1999;27:97–132.
10. Jakobsson J, Perlkvist A, Wann-Hansson C. Searching for evidence regarding using preoperative disinfection showers to prevent surgical site infections: a systematic review. *Worldview Evidence-Based Nurs* 2011;3:143–152.
11. Gignon M, Ammirati C, Mercier R, Detave M. Compliance with emergency department discharge instructions. *Emerg Nurs* 2014;40:51–55.
12. Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR. The effect of reminder systems on patient's adherence to treatment. *Patient Preference Adherence* 2012;6:127–135.
13. Edmiston CE, Krepel CJ, Edmiston SE, et al. Empowering the surgical patient: a randomized, prospective analysis of an innovative strategy for improving patient compliance to the preadmission showering protocol. *J Am Coll Surgeons* 2014;219:256–264.
14. The USP Official Monograph for the identification of chlorhexidine gluconate solution. The United States Pharmacopeia (USP 29). The National Formulary (NF 24). Rockville, MD: The United States Pharmacopeia Convention; 2006: 477–478.
15. Edmiston CE, Krepel CJ, Seabrook GR, Lewis BD, Brown KR, Towne JB. The preoperative shower revisited: can high topical antiseptic levels be achieved on the skin surface prior to surgical admission? *J Am Coll Surg* 2008;207:233–239.
16. Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. *Cochrane Database Syst Rev* 2015 Feb 20;2:CD004985.
17. Edmiston CE, Bruden B, Rucinski M, Hemen C, Graham MB, Lewis BL. Reducing the risk of surgical site infections: does chlorhexidine gluconate provide a risk reduction benefit? *Am J Infect Control* 2013;41:S49–S55.
18. Edmiston CE, Assadian O, Spencer M, Olmsted RN, Barnes S, Leaper D. To bathe or not to bathe with chlorhexidine gluconate: is it time to take a stand for the preadmission shower/cleansing? *AORNJ* 2015;101:529–538.
19. Edmiston CE, Lee CJ, Krepel CJ, et al. Evidence for preadmission showering regimen to achieve maximal antiseptic skin surface concentrations of chlorhexidine gluconate, 4%, in surgical patients. *JAMA Surg* 2015;150:1027–1033.
20. Edmiston CE, Okoli O, Graham MB, Sinski S, Seabrook GR. Improving surgical outcomes: an evidence-based argument for embracing a chlorhexidine gluconate (CHG) preoperative shower (cleansing) strategy for elective surgical procedures. *AORNJ* 2010;92:509–518.
21. Anderson DJ, Podgorny K, Berrios-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* 2014;35:605–627.
22. Edmiston CE, Spencer M, Lewis BD, et al. Reducing the risk of surgical site infections: Did we really think that SCIP would lead us to the promised land? *Surg Infect* 2011;12: 169–177.
23. Leaper D, Tanner J, Kiernan M, Assadian O, Edmiston CE. Surgical site infection: poor compliance with guidelines and care bundles. *Int Wound J* 2015;12:357–362.